Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63723283 plus apalutamide in metastatic castration-resistant prostate cancer
NL-OMON50489Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetrelimab and apalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence and severity of adverse events and PSA response rate at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
cetrelimabapalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON50489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50489.